Tirzepatide (Mounjaro)

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Atherosclerotic Cardiovascular Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
CN
  • Type 2 diabetes (weight-management approval followed in July 2024 per trade press)
Product first approved 2024yicaiglobal.com
JP
  • Mounjaro: type 2 diabetes
Product first approved 2022pj.jiho.jp
EU
  • Mounjaro: type 2 diabetes; the EPAR also lists weight management (adjunct to diet and activity)
Product first approved 2022EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (18)
Type 2 Diabetes
NCT06246799 · The University of Texas Health Science Center at San Antonio
2024-11-07 – 2029-06-30 · Type 2 Diabetes (Adult Onset)
What this study did
NCT05963022 · Eli Lilly and Company
2023-08-21 – 2024-10-09 · Type 2 Diabetes
What this study did
NCT05691712 · Eli Lilly and Company
2023-02-05 – 2024-07-01 · Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
What this study did
NCT04093752 · Eli Lilly and Company
2019-12-09 – 2021-11-24 · Type 2 Diabetes
What this study did
NCT03861052 · Eli Lilly and Company
2019-05-07 – 2021-03-31 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT07165028 · Eli Lilly and Company
2025-10-15 – 2032-08 · Metabolic Dysfunction-Associated Steatotic Liver Disease
What this study did
NCT07671248 · McMaster University
2026-08-01 – 2028-07-31 · Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
What this study did
NCT06630585 · University of Bern
2025-02-14 – 2026-06 · Type 1 Diabetes (T1D)
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT07284511 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2026-05-19 – 2029-01 · Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus
What this study did
NCT07734792 · yifang zhu
2026-09-26 – 2028-07-31 · Acute Ischemic Stroke (AIS)
What this study did
Phase 2 (25)
Type 2 Diabetes
NCT03131687 · Eli Lilly and Company
2017-05-24 – 2018-08-01 · Type 2 Diabetes Mellitus
What this study did
NCT03311724 · Eli Lilly and Company
2017-10-19 – 2018-04-24 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT07825857 · University of Texas Southwestern Medical Center
2026-10-23 – 2031-08 · Methamphetamine Use Disorder
What this study did
NCT07946315 · Brigham and Women's Hospital
2027-01-01 – 2030-05-01 · Idiopathic Intracranial Hypertension (IIH), Pseudotumor Cerebri, Papilledema
What this study did
NCT07527910 · Regeneron Pharmaceuticals
2026-05-22 – 2030-03-15 · Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
What this study did
NCT07091734 · University of Michigan
2025-09-08 – 2029-09 · Lipodystrophy, Partial
What this study did
NCT06939088 · Anders Fink-Jensen, MD, DMSci
2025-05-05 – 2028-12-31 · Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence, Alcoholism, Schizophrenia Disorders, Schizophrenia and Disorders With Psychotic Features, Schizophrenia and Schizophrenia Spectrum Psychosis, Schizophrenia
What this study did
NCT07573163 · Alaa Sada
2026-07-27 – 2028-12-31 · Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; Status
What this study did
NCT07468552 · National Institute on Drug Abuse (NIDA)
2026-11-15 – 2028-11-15 · Cannabis Use Disorder
What this study did
NCT07602699 · University of Southern California
2026-06-05 – 2028-09 · Smoking Cessation, Smoking Behaviors
What this study did
NCT07906041 · Atria Research and Global Health Institute (ARGHI)
2026-10 – 2028-09 · Longevity, Preventive Medicine, Biological Ageing
What this study did
NCT06976853 · Washington University School of Medicine
2025-05-13 – 2028-08 · Crohn Disease (CD)
What this study did
NCT07265752 · Brigham and Women's Hospital
2027-03-01 – 2028-06-30 · Cannabis Use Disorder
What this study did
NCT07734870 · Johns Hopkins University
2026-09-15 – 2028-05-25 · Central Centrifugal Cicatricial Alopecia (CCCA)
What this study did
NCT07676331 · Universitaire Ziekenhuizen KU Leuven
2026-08-01 – 2028-05-01 · Hormone-receptor-positive Breast Cancer, Early Breast Cancer
What this study did
NCT07202247 · City of Hope Medical Center
2025-11-05 – 2028-04-09 · Prostate Carcinoma, Recurrent Prostate Carcinoma
What this study did
NCT07220473 · The University of Texas Medical Branch, Galveston
2026-02-27 – 2028-01 · Aging, LONGEVITY 1
What this study did
NCT07605247 · Rutgers, The State University of New Jersey
2026-06-01 – 2028-01 · Endometrial Cancer
What this study did
NCT06820281 · Victor Chang Cardiac Research Institute
2026-07-07 – 2027-12-31 · Type 1 Diabetes Mellitus
What this study did
NCT06651177 · T. John Winhusen, PhD
2026-01-29 – 2027-10-31 · Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
What this study did
NCT07046819 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)
2026-06-11 – 2027-07-30 · Metabolic Alcohol-associated Liver Disease, Alcohol Use Disorder
What this study did
NCT06727331 · Brigham and Women's Hospital
2025-09-15 – 2027-07-01 · Alcohol Use Disorder (AUD)
What this study did
The Long COVID Treatment Trialactive not recruiting
NCT07128082 · Scripps Translational Science Institute
2025-10-30 – 2026-12 · Long COVID
What this study did
NCT05659368 · Ospedale San Raffaele
2024-01-01 – 2024-12 · Wolfram Syndrome
What this study did
NCT04166773 · Eli Lilly and Company
2019-11-19 – 2024-01-10 · Nonalcoholic Steatohepatitis
What this study did
Phase 1 (19)
Type 2 Diabetes
NCT04050553 · Eli Lilly and Company
2020-02-24 – 2022-01-25 · Diabetes Mellitus, Type 2, Hypoglycemia
What this study did
NCT04235959 · Eli Lilly and Company
2020-10-21 – 2021-08-17 · Diabetes Mellitus, Type 2
What this study did
NCT03951753 · Eli Lilly and Company
2019-06-28 – 2021-04-08 · Diabetes Mellitus, Type 2
What this study did
NCT03322631 · Eli Lilly and Company
2017-11-15 – 2018-11-28 · Type 2 Diabetes Mellitus
What this study did
NCT02759107 · Eli Lilly and Company
2016-05-11 – 2017-06-26 · Healthy, Type 2 Diabetes Mellitus (T2DM)
What this study did
Other / comorbidity
NCT07559500 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)
2026-05-20 – 2031-12-31 · Alcohol Use Disorder (AUD)
What this study did
NCT07782359 · University of Chicago
2026-10-22 – 2030-06 · Lung Cancer
What this study did
NCT07095517 · Massachusetts General Hospital
2026-02-24 – 2028-12-31 · Colorectal Cancer Prevention, Colorectal Adenoma
What this study did
NCT07812636 · Milton S. Hershey Medical Center
2026-11-01 – 2028-08-01 · Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia, Metabolic Comorbidities
What this study did
NCT06890611 · Eli Lilly and Company
2025-03-25 – 2025-09-26 · Healthy
What this study did
NCT05978713 · Eli Lilly and Company
2023-07-31 – 2024-03-12 · Healthy
What this study did
NCT05810597 · Eli Lilly and Company
2023-04-03 – 2023-07-17 · Healthy
What this study did
NCT04172987 · Eli Lilly and Company
2020-02-26 – 2021-02-09 · Healthy
What this study did
NCT04311424 · Eli Lilly and Company
2020-07-28 – 2020-10-02 · Healthy
What this study did
NCT03940742 · Eli Lilly and Company
2019-07-22 – 2020-09-22 · Hepatic Insufficiency
What this study did
NCT04050670 · Eli Lilly and Company
2019-09-13 – 2020-04-03 · Healthy
What this study did
NCT04004988 · Eli Lilly and Company
2019-08-19 – 2019-12-16 · Healthy
What this study did
NCT03482024 · Eli Lilly and Company
2018-03-30 – 2019-08-19 · Renal Insufficiency, End Stage Renal Disease
What this study did
NCT03375463 · Eli Lilly and Company
2017-12-19 – 2018-12-27 · Healthy
What this study did
Phase 4 (12)
Atherosclerotic Cardiovascular Disease
NCT05708859 · Matthew J. Budoff
2024-01-02 – 2026-05 · Type II Diabetes, Atherosclerosis
What this study did
Type 2 Diabetes
NCT06657209 · Stanford University
2025-01-13 – 2027-12-15 · Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes
What this study did
NCT05433584 · Eli Lilly and Company
2022-08-01 – 2027-11 · Type 2 Diabetes
What this study did
NCT05553093 · Nanjing First Hospital, Nanjing Medical University
2022-03-15 – 2027-10-31 · Type 2 Diabetes Mellitus
What this study did
NCT06635057 · Eli Lilly and Company
2024-10-11 – 2026-04-15 · Type 2 Diabetes
What this study did
NCT05564039 · Eli Lilly and Company
2022-11-30 – 2024-08-12 · Type 2 Diabetes
What this study did
NCT05706506 · Eli Lilly and Company
2023-03-08 – 2023-10-31 · Type 2 Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07191873 · Duke University
2026-08-25 – 2028-08 · Idiopathic Intracranial Hypertension (IIH)
What this study did
NCT07706088 · Post Graduate Institute of Medical Education and Research, Chandigarh
2026-07 – 2028-07-01 · Neuropathy, Small Fiber, Diabete Mellitus
What this study did
NCT07483801 · Cambridge University Hospitals NHS Foundation Trust
2026-03 – 2028-04 · Cardiovascular Diseases
What this study did
NCT07756359 · University of North Carolina, Chapel Hill
2027-01-04 – 2027-09 · Pouch, Ileal, Pouches, Ileoanal, Bowel Diseases, Inflammatory
What this study did
NCT06774079 · University of Miami
2025-03-05 – 2027-03-05 · Crohn Disease
What this study did
Early phase / not applicable (3)
Type 2 Diabetes
NCT07303556 · Nazarbayev University
2024-12-18 – 2026-11-01 · Heart Failure, Diabete Type 2, Arterial Hypertension
What this study did
NCT05990374 · Nanjing First Hospital, Nanjing Medical University
2023-08-01 – 2024-01-01 · Diabetes
What this study did
Other / comorbidity
NCT06301256 · Florida Academic Centers Research and Education, LLC
2024-03-11 – 2025-03-11 · Hidradenitis Suppurativa
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Phase 2 (1)
Type 2 Diabetes
NCT07796477 · CSPC Ouyi Pharmaceutical Co., Ltd.
2026-11-06 – 2027-10-19 · T2DM (Type 2 Diabetes Mellitus)
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 2 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tirzepatide (Mounjaro): this drugApprovedPeptideGLP-1/GIP receptor (dual)Partial signal
NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579
NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229)
Acarbose (Precose / Glucobay)
ApprovedUS marketing discontinued
Small moleculeAlpha-glucosidasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results).
Alogliptin (Nesina)ApprovedSmall moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Bexagliflozin (Brenzavvy)ApprovedSmall moleculeSGLT2Reliable signal
NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058)
NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075)
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Partial signal
NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002).
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Colesevelam (Welchol)ApprovedSmall moleculeBile acid sequestrantnot yet gradedNo reviewed efficacy summary in this indication
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Partial signal
NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02)
NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14)
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04)
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1%
NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results).
Ertugliflozin (Steglatro)ApprovedSmall moleculeSGLT2Reliable signal
NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years
NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001).
Glimepiride (Amaryl)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glipizide (Glucotrol)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glyburide (DiaBeta)ApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97)
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)Partial signal
NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07)
NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated.
Insulin Efsitora Alfa (Onswik)ApprovedProtein / enzyme therapeuticInsulin receptor (basal)Partial signal
NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545)
NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424)
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)Partial signalNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062)
NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067)
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061)
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptorPartial signal
NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly.
Insulin Icodec (Awiqli)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89)
NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12)
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptorReliable signalFeatured results are non-efficacy only in this race
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptorPartial signal
NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061)
NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042)
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Linagliptin (Tradjenta)ApprovedSmall moleculeDPP-4Partial signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptorReliable signal
NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07)
NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001)
Lixisenatide (Adlyxin / Lyxumia)ApprovedPeptideGLP-1 receptorPartial signal
NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054)
NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119)
Metformin (Glucophage)
ApprovedUS marketing discontinued
Small moleculeAMPKReliable signal
NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%)
Pioglitazone (Actos)ApprovedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
SAR341402ApprovedPeptideInsulin receptorPartial signal
NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041)
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Sitagliptin (Januvia)ApprovedSmall moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Tirzepatide (Zepbound)
Approved(overall)
PeptideGLP-1/GIP receptor (dual)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Miglitol (Glyset)US approval withdrawnSmall moleculeAlpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
Repaglinide (Prandin / NovoNorm)US approval withdrawnSmall moleculeSUR1 (short-acting)Partial signalNo reviewed efficacy summary in this indication
AlbenatidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorWeak signal
NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo
Anagliptin (Suiny)Phase 3Small moleculeDPP-4Partial signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
ASC30Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 3Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Reliable signal
NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo
NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
BofanglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Brenipatide
Phase 3(overall)
PeptideGLP-1/GIP receptor (dual)
not yet graded(overall)
No reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21).
Chiglitazar (Bilessglu)Phase 3Small moleculePPAR (pan-agonist)Reliable signal
NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008.
NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740)
CofrogliptinPhase 3Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Dapagliflozin / Linagliptin (Dapalina)Phase 3Small moleculeSGLT2;DPP-4Partial signal
NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001
Dorzagliatin (Huatangning)Phase 3Small moleculeGlucokinasePartial signal
NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30).
EfpeglenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care).
Efsubaglutide AlfaPhase 3Protein / enzyme therapeuticGLP-1 receptorReliable signal
NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero.
NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001)
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signal
NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2Reliable signal
NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35%
NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%).
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Evogliptin (Suganon)Phase 3Small moleculeDPP-4Reliable signal
NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001)
NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority.
Exendin-4 Fc Fusion (JY09)Phase 3Protein / enzyme therapeuticGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
HDM1005Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistReliable signalNo reviewed efficacy summary in this indication
ObicetrapibPhase 3Small moleculeCETPnot yet gradedNo reviewed efficacy summary in this indication
OlatorepatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptorPartial signal
NCT05872620: Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001)
NCT05803421: Primary endpoint, time to first MACE-4 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for unstable angina), non-inferiority with margin 1.8 on the upper 95% CI bound of the hazard ratio: 57/1358 (4.2%) orforglipron vs 67/1343 (5.0%) insulin glargine; HR 0.84 (95% CI 0.59 to 1.20; p<0.0001 for non-inferiority), met.
RAY1225Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)Partial signal
NCT05929079: Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract.
NCT06354660: Change in HbA1c from baseline (7.9%) at Week 40: 4 mg -1.7%, 9 mg -2.0%, 12 mg -1.9%, placebo -0.8%; retatrutide met the primary endpoint.
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)Partial signal
NCT06650007: Change in HbA1c from baseline (efficacy estimand): maximum mean reduction of 2.67% with once-weekly ribupatide injection (4 mg and 2 mg) vs placebo
NCT06649344: Primary, HbA1c change from baseline to week 36 (non-inferiority vs semaglutide 1 mg, efficacy estimand): ribupatide 4 mg -2.78%, 2 mg -2.34%, semaglutide -2.29%; non-inferiority achieved for both doses (margin and CI not published), and 4 mg statistically superior to semaglutide, met.
VK2735Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
NNC0519-0130Phase 2PeptideGLP-1/GIP receptor (dual)Weak signalNo reviewed efficacy summary in this indication
THDBH120
Phase 2(overall)
PeptideGLP-1/GIP receptor (dual)
Weak signal(overall)
No reviewed efficacy summary in this indication
KP405
Phase 1(overall)
PeptideGLP-1/GIP receptor (dual)
Partial signal(overall)
No reviewed efficacy summary in this indication

Large race: only the 76 furthest-along competitors are listed; 78 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

2 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(36 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tirzepatide (Mounjaro) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Long COVIDActive not recruiting
Est. primary completion 2026-12 · NCT07128082 · CT.gov ↗
What to watch
2027 (11)
March 2027 (3)
Phase 2Alcohol Use Disorder (AUD)Recruiting
Est. primary completion 2027-03-01 · NCT06727331 · CT.gov ↗
What to watch
Phase 4Crohn DiseaseActive not recruiting
Est. primary completion 2027-03-05 · NCT06774079 · CT.gov ↗
What to watch
Phase 1Colorectal Cancer Prevention, Colorectal AdenomaRecruiting
Est. primary completion 2027-03-31 · NCT07095517 · CT.gov ↗
What to watch
April 2027 (1)
Phase 4Cardiovascular DiseasesNot yet recruiting
Est. primary completion 2027-04 · NCT07483801 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Metabolic Alcohol-associated Liver Disease, Alcohol Use DisorderRecruiting
Est. primary completion 2027-07-30 · NCT07046819 · CT.gov ↗
What to watch
August 2027 (1)
Phase 4Idiopathic Intracranial Hypertension (IIH)Recruiting
Est. primary completion 2027-08 · NCT07191873 · CT.gov ↗
What to watch
September 2027 (2)
Phase 4Pouch, Ileal, Pouches, Ileoanal, Bowel Diseases, InflammatoryRecruiting
Est. primary completion 2027-09 · NCT07756359 · CT.gov ↗
What to watch
Phase 2Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, SevereRecruiting
Est. primary completion 2027-09-30 · NCT06651177 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Aging, LONGEVITY 1Recruiting
Est. primary completion 2027-11 · NCT07220473 · CT.gov ↗
What to watch
December 2027 (2)
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-12-15 · NCT06657209 · CT.gov ↗
What to watch
Phase 2Type 1 Diabetes MellitusRecruiting
Est. primary completion 2027-12-31 · NCT06820281 · CT.gov ↗
What to watch
2028 (16)
January 2028 (2)
Phase 2Endometrial CancerNot yet recruiting
Est. primary completion 2028-01 · NCT07605247 · CT.gov ↗
What to watch
Phase 2/3Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes MellitusRecruiting
Est. primary completion 2028-01 · NCT07284511 · CT.gov ↗
What to watch
March 2028 (3)
Phase 2Smoking Cessation, Smoking BehaviorsRecruiting
Est. primary completion 2028-03 · NCT07602699 · CT.gov ↗
What to watch
Phase 2Hormone-receptor-positive Breast Cancer, Early Breast CancerNot yet recruiting
Est. primary completion 2028-03-01 · NCT07676331 · CT.gov ↗
What to watch
Phase 2Cannabis Use DisorderNot yet recruiting
Est. primary completion 2028-03-15 · NCT07468552 · CT.gov ↗
What to watch
April 2028 (2)
Phase 2Longevity, Preventive Medicine, Biological AgeingEnrolling by invitation
Est. primary completion 2028-04 · NCT07906041 · CT.gov ↗
What to watch
Phase 2Prostate Carcinoma, Recurrent Prostate CarcinomaRecruiting
Est. primary completion 2028-04-09 · NCT07202247 · CT.gov ↗
What to watch
May 2028 (4)
Phase 2Crohn Disease (CD)Recruiting
Est. primary completion 2028-05 · NCT06976853 · CT.gov ↗
What to watch
Phase 1Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia, Metabolic ComorbiditiesNot yet recruiting
Est. primary completion 2028-05-01 · NCT07812636 · CT.gov ↗
What to watch
Phase 2Central Centrifugal Cicatricial Alopecia (CCCA)Recruiting
Est. primary completion 2028-05-25 · NCT07734870 · CT.gov ↗
What to watch
Phase 2/3Acute Ischemic Stroke (AIS)Recruiting
Est. primary completion 2028-05-31 · NCT07734792 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Cannabis Use DisorderNot yet recruiting
Est. primary completion 2028-06-30 · NCT07265752 · CT.gov ↗
What to watch
July 2028 (3)
Phase 4Neuropathy, Small Fiber, Diabete MellitusNot yet recruiting
Est. primary completion 2028-07-01 · NCT07706088 · CT.gov ↗
What to watch
Phase 2Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; StatusRecruiting
Est. primary completion 2028-07-31 · NCT07573163 · CT.gov ↗
What to watch
Phase 3Cannabis Use Disorder, Moderate, Cannabis Use Disorder, SevereNot yet recruiting
Est. primary completion 2028-07-31 · NCT07671248 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence, Alcoholism, Schizophrenia Disorders …Recruiting
Est. primary completion 2028-08-01 · NCT06939088 · CT.gov ↗
What to watch
2029 (2)
April 2029 (1)
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2029-04-30 · NCT06246799 · CT.gov ↗
What to watch
September 2029 (1)
Phase 2Lipodystrophy, PartialRecruiting
Est. primary completion 2029-09 · NCT07091734 · CT.gov ↗
What to watch
2030 (4)
March 2030 (1)
Phase 2Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Recruiting
Est. primary completion 2030-03-15 · NCT07527910 · CT.gov ↗
What to watch
May 2030 (1)
Phase 2Idiopathic Intracranial Hypertension (IIH), Pseudotumor Cerebri, PapilledemaNot yet recruiting
Est. primary completion 2030-05-01 · NCT07946315 · CT.gov ↗
What to watch
June 2030 (1)
Phase 1Lung CancerRecruiting
Est. primary completion 2030-06 · NCT07782359 · CT.gov ↗
What to watch
August 2030 (1)
Phase 3Metabolic Dysfunction-Associated Steatotic Liver DiseaseRecruiting
Est. primary completion 2030-08 · NCT07165028 · CT.gov ↗
What to watch
2031 (2)
July 2031 (1)
Phase 2Methamphetamine Use DisorderRecruiting
Est. primary completion 2031-07-01 · NCT07825857 · CT.gov ↗
What to watch
December 2031 (1)
Phase 1Alcohol Use Disorder (AUD)Recruiting
Est. primary completion 2031-12-31 · NCT07559500 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 August 2026ApprovalFDA approves Mounjaro to reduce cardiovascular risk in type 2 diabetes
US, FDA · Source ↗
27 August 2026ApprovalFDA Boxed Warning on Mounjaro (NDA215866)
US, FDA · FDA · Source ↗
20 December 2024ApprovalFDA approves Zepbound for obstructive sleep apnea in adults with obesity
US, FDA · Source ↗